Safety and tolerance of a new extensively hydrolyzed rice protein-based formula in the management of infants with cow’s milk protein allergy by Yvan Vandenplas et al.
ORIGINAL ARTICLE
Safety and tolerance of a new extensively hydrolyzed rice
protein-based formula in the management of infants with cow’s
milk protein allergy
Yvan Vandenplas & Elisabeth De Greef & Bruno Hauser &
Paradice Study Group
Received: 26 December 2013 /Revised: 3 March 2014 /Accepted: 24 March 2014 /Published online: 12 April 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Guidelines recommend the use of extensively hy-
drolyzed cow’s milk protein-based formulas (eHF) in the
treatment of infants with cow’s milk protein allergy
(CMPA). Extensively hydrolyzed rice protein infant formula
(eRHF) has recently become available and could offer a valid
alternative. A prospective trial was performed to evaluate the
hypo-allergenicity and safety of a new eRHF in infants with a
confirmed CMPA. Patients were fed the study formula for
6 months. Clinical tolerance of the eRHFwas evaluated with a
symptom-based score (SBS) and growth (weight and length)
was monitored. Forty infants (mean age, 3.4 months; range,
1–6 months) with CMPA confirmed by a food challenge were
enrolled. All infants tolerated the eRHF and the SBS signifi-
cantly decreased as of the first month of intervention.
Moreover, the eRHF allowed a catch-up to normal weight
gain as of the first month as well as a normalization of the
weight-for-age, weight-for length, and BMI z-scores within
the 6-month study period. Conclusion: In accordance with
current guidelines, this eRHF was tolerated by more than
90 % of children with proven CMPAwith a 95 % confidence
interval. This eRHF is an adequate and safe alternative to cow
milk-based eHF.
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Introduction
Guidelines for the dietary management of infants diag-
nosed with cow’s milk protein allergy (CMPA) recom-
mend the substitution of cow’s milk with extensively
hydrolyzed casein or whey protein formulas (eHF) [3,
4, 6, 13]. Up to 14 % of infants with CMPA will also
react to soy infant formula (SIF) [1, 4], even though
tolerance of soy is better in immunoglobulin E (IgE)
compared with non-IgE-media ted CMPA [27] .
ESPGHAN and an Australian expert panel recommend
not using SIF before the age of 6 months [12, 13]. In
addition, the American Academy of Pediatrics (AAP)
recommends an eHF as a preferred therapeutic option
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with SIF as a second choice [4]. However, eHFs are substan-
tially more expensive than standard or soy infant formulae and
generally have a bitter taste, which often hampers their ac-
ceptability [4]. Moreover, some parents may look for vegeta-
ble alternatives due to various opinion or convictions. Some
infants may still be intolerant or allergic to these eHFs [3, 6,
13]. In those cases, amino acid formulae (AAF) are an effec-
tive dietary treatment [4, 6, 13] but are even substantially more
expensive and have also a bitter taste.
As a result, affordable and better-tasting dietary options in
the treatment of CMPAwould be welcomed as an alternative.
Hydrolyzed formulas based on rice protein may offer such an
option [7, 9, 10, 19, 20]. Therefore, the efficacy of such a new
extensively hydrolyzed rice protein infant formula (eRHF)
was evaluated in infants with CMPA.
Materials and methods
This study was conducted between April 2011 and March
2013. Infants who initially presented with symptoms suggest-
ing CMPAwere selected. Diagnostic criteria to suspect CMPA
were based on the presence of a combination of the following
symptoms: general discomfort (persistent distress or colic,
>3 h/day and wailing/irritability at least 3 days/week since at
least 1 week), gastrointestinal signs and symptoms (frequent
regurgitation, vomiting, diarrhoea, constipation with or with-
out perianal rash, and blood in the stools), respiratory symp-
toms (runny nose, otitis media, chronic cough, and wheezing
unrelated to infection), and dermatological manifestations
(atopic dermatitis, angio-oedema, urticaria unrelated to acute
infections, drug intake, etc.) [13, 23, 25]. A symptom-based
Table 1 Symptom-based clinical score (adapted from refs. [20, 23, 24])
Symptom Score
Cryinga 0 to 6 0 1 h/day
1 1–1.5 h/day
2 1.5–2 h/day
3 2 to 3 h/day
4 3 to 4 h/day
5 4 to 5 h/day
6 >5 h/day
Regurgitation [22] 0 to 6 0 0–2 episodes/day
1 >3 to <5 of small volume
2 >5 episodes of >1 coffee spoon
3 >5 episodes of±half of the feedings in<half of the feedings
4 Continuous regurgitations of small volumes >30 min after each feeding
5 Regurgitation of half to complete volume of a feeding in at least half of the feedings
6 Regurgitation of the complete volume after each feeding
Stools (according to
Bristol stool scale [15])
0 to 6 4 Types 1 and 2 (hard stools)
0 Types 3 and 4 (normal stools)
2 Type 5 (soft stool)
4 Type 6 (mushy/liquid stool, if unrelated to infection)
6 Type 7 (watery stools)






0 to 6 Urticaria (0 no/6 yes)




a Crying was only considered if the child was crying for 1 week or more, assessed by the parents, without any other obvious cause
1210 Eur J Pediatr (2014) 173:1209–1216
score (SBS) considering the vast majority of the symptoms of
CMPA reported in literature was developed and the severity of
each presenting symptom was scored (Table 1) [21, 24, 25].
Infants were included after the diagnosis of CMPA was
confirmed by a positive challenge, except if the challenge was
contra-indicated, in accordance to recent guidelines [13]. The
challenge was performed with standard infant formula, fol-
lowing a standardised challenge test procedure [13]. The
challenge procedure lasted one week, of which the first half
day consisted of gradual introduction of cow’s milk protein
(CMP). If no reaction occurred during this half day, parents
administered at least 250 ml/day of standard infant formula
per day during 1 week. During that week, on a daily basis,
parents had to fill in a diary with information on regurgitation,
stools, and duration of crying. Parents had to report any
change/reaction they noticed. If any, the child was presented
at the outpatient clinic and the physician evaluated the evolu-
tion of the SBS. The paediatricians evaluated the SBS before
and during the food challenge, as well as 1, 3, and 6 months
after initiation of the dietary treatment with the eRHF.
Baseline score was defined as the score reached when a
positive reaction occurred during the challenge, both for im-
mediate and late reactions. It was up to the physician to decide
to perform a skin-prick test (SPT) and measure-specific IgE.
The SPTwas evaluated according to the standard criteria, i.e.,
a papula of 3 mm induration compared with a negative control
with saline solution [8].
A positive challenge was the inclusion criterion for this
study; included infants were fed with the new eRHF during
6 months. Infant formulas are the only recommended food for
infants below 6 months. Weaning foods were introduced
following paediatricians’ advice, with specific recommenda-
tion to avoid cow’s milk containing products.
The SBS was evaluated 1, 3, and 6 months after initiation
of the dietary treatment with the eRHF. Growth (weight and
length) was monitored and evaluated as z-scores according to
the WHO Child Growth Standards [26]. Feeding tolerance
and adverse events were registered throughout the 6 months
study period.
The test formula (NovaRice, United Pharmaceuticals) con-
tains extensively hydrolyzed-rice protein supplemented with
lysine and tryptophan to improve the nutritional quality by
providing an amino-acid profile similar to that of mother’s
Table 2 Average nutritional composition of the study formula
Unit /100 g /100 ml
Proteins g 13.4 1.8
Fats g 25.5 3.4
Saturated fatty acids g 9.9 1.3
Monounsaturated fatty acids g 9.2 1.2
Polyunsaturated fatty acids g 5.1 0.7
Linoleic acid g 4.5 0.6
Alpha-linolenic acid mg 425 57.4
Medium-chain triglycerides g 2.3 0.3
Carbohydrates g 49 6.6
Maltodextrins g 46 6.2
Starch g 1 0.1
Fibers g 4 0.5
Fibers g 4 0.5
Energy kcal 487 65.7
The composition of the formula may be adjusted for compliance to
various regulations, without any impact on the hypoallergenicity of the
formula, and its nutritional value
Selected patients 
N=42




Poor taste  (N = 2)
Visit Day 30 (N=38)
Drop out:
Poor taste (N = 1 )
Lost to follow up (N = 1)
Visit Day 90 (N=36)
Visit Day 180 (N=36)
Fig. 1 Flow chart
Table 3 Description of the included population
Boy/girl 21/19
Age at inclusion (months) mean+SD 3.4+±1.5
Median (range) 3 (0–6)
Time since the first apparition of the symptoms (months),
mean±SD
1.9±1.2
Median (range) 1.8 (0.2–5.4)
Infants never breast fed (n (%)) 9 (23.1)
Duration of exclusive breast feeding (weeks), mean±SD 5.2±5.0
Median (range) 4 (0–18)
Duration of partial breast feeding (weeks; mean±SD) 2.3±4.0
Median (range) 1 (0–16)
Infants with at least one parent or sibling having a proven
or suspected allergic disease (n (%))
36 (90.0)
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milk, in compliance with the recommendation of the EU
Directive on infant formulas (composition of the formula,
Table 2). More than 95 % of the peptides in the eRHF have
a molecular weight of less than 3 kDa, and most of these are
under 1.5 kDa. It also contains a thickening complex using
pectin, as extensive hydrolysates are particularly liquid. The
formula is lactose free and complies with EU regulation.
The study was approved by the Ethical Committee of the
UZ Brussel, acting as the leading center, and of each partici-
pating center; 14 investigators from 11 centers participated in




























a Paired Student’s t test
Table 5 Evolution of the differ-




















<3 h/day 26 (68.4) 16 (42.1) 38 ( 100) 36 (100) 36 (100)
≥3 h/day 12 (31.6) 22 (57.9) 0 (0) 0 (0) 0 (0)
p A–B, 0.0001c A–C, <0.0001c A–D, <0.0001c
Crying score
Mean±SD 2.2±1.8 3.8±2.0 0.5±0.8 0.2±0.4 0.1±0.4
p A–B,
<0.001d
A–C, <0.001d A–D, <0.001d
Regurgitation score [22]
Mean±SD 1.5±1.9 2.4±2.2 0.6±0.9 0.5±0.9 0.1±0.3
p A–B, 0.001d A–C, <0.001d A–D, <0.001d
Stools (n (%))
Normal stools (type III or IV) 5 (13.2) 2 (5.3) 20 (52.6) 21 (58.3) 28 (77.8)
Abnormal stools (type I, II, V,
VI, or VII)
33 (86.8) 36 (94.7) 18 (47.4) 15 (41.7) 8 (22)
p <0.0001c <0.0001c <0.0001c
Urticaria (n (%))
2 (5.3) 6 (15.8) 0 (0.0) 0 (0.0) 0 (0.0)
p <0.02c <0.02c <0.02c
Eczema (n (%)), head, neck, trunk (n (%))
Absent 23 (60.5) 18 (47.4) 30 (78.9) 31 (86.1) 31 (86.1)
Mild 7 (18.4) 6 (15.8) 7 (18.4) 4 (11.1) 4 (11.1)
Moderate 7 (18.4) 10 (26.3) 1 (2.6) 1 (2.8) 1 (2.8)
Severe 1 (2.6) 4 (10.5) 0 0 0
p <0.05a <0.05a <0.05a
Arms, hands, legs, and feet (n (%))
Absent 27 (71.1) 23 (60.5) 33 (86.8) 33 (91.7) 32 (88.9)
Mild 2 (5.3) 3 (7.9) 5 (13.2) 3 (8.3) 4 (11.1)
Moderate 7 (18.4) 8 (21.1) 0 0 0
Severe 2 (5.3) 4 (10.5) 0 0 0
p 0.055a 0.02a 0.058a
Respiratory symptoms (n (%))
Absent 31 (81.6) 29 (76.3) 31 (81.6) 27 (75 %) 29 (80.6 %)
Light 5 (13.2) 6 (15.8) 5 (13.2) 8 (22.2) 5 (13.9
Mild 1 (2.6) 2 (5.3) 2 (5.3) 1 (2.8) 1 (2.8)
Severe 1 (2.6) 1 (2.6) 0 (0.0) 0 (0.0) 1 (2.8)
p NS NS NS
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the trial. A written informed consent was obtained from all
parents. United Pharmaceuticals provided free formula for the
study period. The study was registered at clinicaltrials.gov
NCT number NCT01998074
To be considered hypoallergenic, a therapeutic formula
must demonstrate in a clinical study that with 95% confidence
it does not provoke allergic reactions in 90 % of infants or
children with confirmed cow’s milk allergy [3]. In case of no
reaction, the lower 95 % confidence interval (CI) for the
proportion of patients with no reaction should be greater than
90 %; a sample size of 29 participants is sufficient to show
hypo-allergenicity. Considering possible dropouts or devia-
tion to inclusion criteria, the target was to recruit 36 patients.
Statistical analysis was carried out using SAS 9.2 software.
For qualitative parameters classified in two categories,
McNemar’s test was used and in case of more than 2 catego-
ries, symmetry test was used. Paired Student’s t test was used
for quantitative parameters. The normality of distribution was
systematically checked using Shapiro–Wilk’s test and the
Wilcoxon’s test was used in case of non-normality.
Results
Forty-two patients were selected for the study. Forty
infants were included (21 boys, 19 girls; age, 3.4+
1.5 months (mean+SD); range, 0–6 months) (Fig. 1;
Table 3). Thirty-eight infants had a positive challenge
confirming CMPA and two patients were not challenged
because of an initial anaphylactic reaction. This was the
intention to treat population, used to assess the hypo-
allergenicity and growth parameters evolution. Fourteen
out of 38 infants had an immediate type of reaction. A
SPT was performed in 17 infants and was positive in 15
(mean wheal, 11 mm (range, 3–25 mm)).
Four patients dropped out before the end of the study
(Fig. 1). Three parents decided to stop the trial because ac-
cording to their opinion the infant did not like or accept the
study formula and preferred the “initial” formula (which was
given before the challenge). One patient did not show up for
the visit after 1 month.
The tolerance was evaluated on the intention-to-treat pop-
ulation of 40 patients, consisting of all patients with a con-
firmed CMPA. None of them dropped out for intolerance.
Seventy-nine adverse events have been reported during the
6 months observation period. Among them, five were serious
adverse events all unrelated to the study formula (two bron-
chiolitis, one pneumonia, and two pyelonephritis). One non-
serious adverse event was reported as related to the study
product, it was food refusal leading to the end of the study
for this patient. Other adverse events were mainly related
mainly to ear-nose-throat (73 %), gastro-intestinal tract
infections (14.9 %), or varicella (4.1 %), the remaining
(8 %) being various such as fever, conjunctivitis.
The SBS change was evaluated on the 38 allergic infants
who were presented after one month eRHF feeding. Thirty-six
out of 38 were fed the study formula for 6 months.
The SBSwas significantly lower at each time point (1, 3, or
6 months) than at baseline (Table 4, p<0.001).
All parameters composing the SBS score had decreased
after 1 month of dietary treatment with the study formula
(Table 5), and this evolution was confirmed after 3 and
6 months. At baseline, 5.3 % of the infants had “normal”
stools while after only one month feeding with the eHRF
Table 6 Anthropometric data at inclusion and after 1, 3, and 6 months
feeding with the extensive rice hydrolysate
Inclusion 1 month 3 months 6 months
Age (months)
No. of subjects (N) 40 38 36 36
Mean±SD 3.4±1.5 4.4±1.5 6.4±1.6 9.6±1.7
Range 1–6 2–7 4–10 7–13
Weight (kg)
N 38 38 36 36
Mean±SD 6.1±1.1 6.7±1.1 7.6±1.1 8.8±1
Weight-for-age z-score
Mean±SD −0.7±1.0 −0.5±0.9 −0.3±1.0 −0.1±0.9
p (visit inclusion) <0.001b <0.001a <0.001a
Length (cm)
N 37 38 36 36
Mean±SD 61.9±3.9 64.3±3.7 67.8±3.5 72.1±3.3
Length-for age z-score
Mean±SD −0.1±1.0 −0.1±1.1 −0.1±1.1 −0.1±1.1
p (visit inclusion) NSa NSa NSa
Weight-for-length z-score
Mean±SD −0.7±0.9 −0.5±0.8 −0.3±0.9 0±0.8
p (visit inclusion) 0.018a <0.001a <0.001a
BMI (kg/m2)
N 37 38 36 36
Mean±SD 15.7±1.6 16.2±1.4 16.5±1.3 16.8±1.2
BMI-for-age z-score
Mean±SD −0.7±0.9 −0.6±0.8 −0.4±0.9 0.0±0.8
p (visit inclusion) 0.012a <0.001a <0.001a
Head circumference (cm)
N 37 38 36 36
Mean±SD 40.8±1.9 42.1±1.6 43.6±1.8 45.5±1.6
Head circumference z-score
Mean±SD 0.1±1.1 0.3±0.9 0.3±1.2 0.5±1.0
p (visit inclusion) 0.020b NSa <0.001a
p values are related to z-score variation between inclusion and each visit
a Student’s t test
bWilcoxon’s test
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52.6 % had normal stools (p<0.0001). At the end of the 6-
month period, 77.8 % of the infants had normal stools. At
baseline, 57.9 % of the infants were crying more than 3 h/day,
whereas, after 1 month, none of the infants were crying more
than 3 h/day (p<0.0001), and 65.8 % were crying less than
1 h/day. At three months, 86.1 % of the infants were crying
less than 1 hour a day. The regurgitation score [24]
decreased by 75 % over 1 month (from 2.4+2.2 to
0.6+0.9, p<0.0001), and this decrease persisted at days
90 (0.5+0.9) and 180 (0.1+0.3).
Thirty-six infants were fed with the study formula for at
least 6 months. Growth parameters were evaluated as z-scores
according to the WHO Child Growth Standards [21] and are
shown in Table 6 and Fig. 2. At inclusion, weight-for-
Fig. 2 Evolution of weight-for-age z-score for boys and girls
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age, weight-for-length, and BMI z-scores were all negative
(−0.7) indicating a slight growth faltering. As of the 1st month
of feeding with the study formula, the weight-for-age, weight-
for-length, and BMI z-scores significantly increased and were
normalized with a catching up of the WHO Child Growth
Standards by the end of the study period.
Discussion
This extensively hydrolyzed rice protein formula was tolerat-
ed by infants with a proven CMPA and contributed to catch-
up growth. To date, all studies with hydrolyzed rice protein
formulas (RHF) were performed with a partial rice protein
hydrolysate (pRHF). Nevertheless, these studies also focused
on their tolerance in infants with CMPA [9, 10, 19]. Two
studies by Fiocchi et al have shown that infants with CMPA
and other food allergies tolerated pRHF [9, 10]. Reche et al.
demonstrated a 95% efficacy rate with a pRHF in infants with
CMPA [19]. We demonstrated a 100 % efficacy rate with this
eRHF.
Despite the doubts raised in an article [20] regarding the
nutritional adequacy of pRHF, growth was shown to be ade-
quate in this trial as well as in other studies carried out using a
pRHF in infants with CMPA [2, 14]. A normalization of the
weight-for-age, weight-for-length, and BMI was observed in
those infants presenting on average a faltering growth at
inclusion (mean weight-for-age, weight-for-length, and BMI
z-scores of −0.7).
Rice has also recently been criticized regarding its possible
arsenic content. However, this concerned mainly organic
brown rice syrup and was not related to infant formula based
on extensively hydrolyzed rice protein. There is no EU regu-
lation fixing limits to arsenic in infant formulas. In particular,
this study formula contains less than 10μg/L of arsenic, which
is the maximum content allowed in drinking water according
to EU regulation [5] (drinking water being the only food in
which arsenic content is regulated) and infant formulas are
reconstituted with approximately 86 to 87 % of water. In this
study, the rice-protein based formula was generally well tol-
erated, with parents of three patients ending the study formula
with the argument that their infant did not like the taste of the
formula. In general, one of the main complaints of parents is
that infants refuse hydrolyzed formulas because of their un-
pleasant bitter taste. A double-blind study evaluating the
palatability of different formulas used to feed infants with
CMPA showed that soy and rice-based formulas had better
taste scores than CMP hydrolyzed formulas [18]. Good ac-
ceptability because of its pleasant odor, taste, and flavor was
confirmed for rice formulas in healthy infants [9, 19]. In this
study, while acceptance was not unanimous, 81.2 % of the
parents reported that infants liked the taste of the formula.
Moreover, in this study, a normalization of the stool’s
consistency was observed as of the first month of feeding with
the thickened eRHF whereas frequent and/or liquid stools are
often associated with feeding children with hydrolyzed pro-
tein formula [17] (before the challenge, only 13.2 % of the
infants had normal stools; Table 7).
Hydrolyzed formulas are very liquid. Although they have
been reported in literature to not increase regurgitation [11],
there are conflicting data suggest they increase the frequency
of regurgitation by 18 % [16]. In this study, regurgitation
decreased significantly during the first month of feeding with
the thickened eRHF. The same thickening complex was added
to en extensive hydrolysed CMP (casein) based formula and
had similar beneficial effects on normalization of stool con-
sistency as well as a decrease of regurgitation in infants with
CMPA [21]. Besides efficacy, nutritional value and accept-
ability, the cost of infant formula is also of importance as
affordability may promote compliance. While cost of infant
formulas differ from country to another, overall it can be said
that the cost of eRHF is significantly less than one of an
extensive cow milk hydrolysate.
In conclusion, the study formula was tolerated by more
than 90 % of infants with a demonstrated CMPA, with a 95 %
CI. The formula also ensured a proper growth of those infants.
The excellent acceptability of the eRHF tested makes this kind
of formula an interesting option in the treatment of CMPA in
terms of efficacy, nutritional value, affordability, acceptance,
and tolerance. However, more studies with a greater number
of subjects targeting safety, anthropometric growth and devel-
opment with these new formulas are needed.
Table 7 Evolution of stool consistency according to the Bristol stool scale
Before challenge At inclusion 1 month 3 months 6 months
Type 1 or 2: separate hard lumps, like nuts (hard to pass),
or sausage-shaped, but lumpy
11 (28.9 %) 9 (23.7 %) 3 (7.9 %) 2 (5.6 %) 0 (0 %)
Type 3 or 4: like a sausage or snake smooth and soft 5 (13.2 %) 2 (5.3 %) 20 (52.6 %) 21 (58.3 %) 28 (77.8 %)
Type 5: soft blobs with clear cut edges (passes easily) 9 (23.7 %) 4 (10.5 %) 4 (10.5 %) 8 (22.2 %) 5 (13.9 %)
Type 6: fluffy pieces with ragged edges, a mushy stool 9 (23.7 %) 11 (28.9 %) 10 (26.3 %) 5 (13.9 %) 2 (5.6 %)
Type 7: watery, no solid pieces, or entirely liquid 4 (10.5 %) 12 (31.6 %) 1 (2.6 %) 0 (0 %) 1 (2.8 %)
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